Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Top Cited Papers
Open Access
- 10 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-13
- https://doi.org/10.1038/s41467-021-22874-x
Abstract
Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resistance and acquired resistance to the drugs are major clinical issues. To understand the molecular underpinnings of clinical resistance to IDH inhibitors (IDHi), we perform multipronged genomic analyses (DNA sequencing, RNA sequencing and cytosine methylation profiling) in longitudinally collected specimens from 60 IDH1- or IDH2-mutant AML patients treated with the inhibitors. The analysis reveals that leukemia stemness is a major driver of primary resistance to IDHi, whereas selection of mutations in RUNX1/CEBPA or RAS-RTK pathway genes is the main driver of acquired resistance to IDHi, along with BCOR, homologous IDH gene, and TET2. These data suggest that targeting stemness and certain high-risk co-occurring mutations may overcome resistance to IDHi in AML.This publication has 38 references indexed in Scilit:
- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLBlood Advances, 2020
- SJARACNe: a scalable software tool for gene network reverse engineering from big dataBioinformatics, 2018
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutationsNature, 2018
- Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cellsNature, 2018
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood, 2017
- Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probesNucleic Acids Research, 2016
- ( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are ReversibleScience, 2013
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotypeBlood, 2011
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1αScience, 2009